ArticleMedicine2025
Chinese herbal medicine on the offspring of women with polycystic ovary syndrome: A retrospective cohort study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is a common female reproductive endocrine disease, which increases the long-term health risks of the offspring. Chinese herbal medicine (CHM) has demonstrated significantly positive effects in treating PCOS. However, the effects of preconception administration of CHM on the offspring of the women with PCOS need to be elucidated. This study aimed to investigate the effects of a patented CHM (Bu-Shen-Tian-Jing Formula) on the offspring of women with PCOS. This study was designed as a retrospective cohort study. A total of 75 PCOS women, who achieved successful pregnancy through letrozole-induced ovulation and delivered successfully, were divided into CHM group (n = 38, treated with Bu-Shen-Tian-Jing Formula before the treatment of letrozole) and non-CHM group (n = 37, without CHM treatment). The information of the women with PCOS and their children (at birth) was collected from the Hangzhou City Community Health Service Information System. The included mothers were invited to complete the Ages and Stages Questionnaire, Third Edition to China and the Chinese version of Ages and Stages Questionnaire Social-Emotional, Second Edition to screen the developmental delays of the offspring. The total incidence rate of pregnancy complications was significantly higher in non-CHM group compared with CHM group (P = .001). The height of the children in CHM group was significantly lower than non-CHM group at 6 months old (P = .038). The head circumference of children in CHM group was significantly larger than the non-CHM group respectively at 24 and 36 months old (P = .047 and P = .030). The proportions of "above cutoff value" in fine motor and problem-solving domains of the children in the CHM group were significantly higher than non-CHM group (P = .003 and P = .022) and the proportions of "below cutoff value" in the CHM group were significantly smaller than the non-CHM group (P = .024). Preconception administration of CHM significantly decreased the incidence of pregnancy complications in the women with PCOS undergoing letrozole-induced ovulation and improved the development of the offspring. However, it may be limited by the relatively small sample size and the simple evaluation indicators.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.